NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a rapidly growing medical device company, announced today that key opinion leading physicians are recognizing the significant clinical and economic benefits of noninvasive hemodynamic monitoring during perioperative fluid management.

Cheetah Medical hosted a non-CME educational symposium —“Clinical and Economic Considerations of Non-Invasive Hemodynamic Monitoring in Perioperative Fluid Management”—on Sunday, Oct. 12, during the annual scientific meeting of the American Society of Anesthesiologists (ASA). Faculty included: Prof. Michael (Monty) Mythen, University College Hospital, UK; Dr. Paul Heerdt, Weill Medical College, Cornell University; and, Dr. Thomas Hopkins, Duke University Hospital.

“Key opinion leaders are recognizing the increased patient benefits and the decreased costs associated with fluid management. The FDA-cleared and CE-marked CHEETAH NICOM system is completely noninvasive and, using the power of Bioreactance®, is designed to be the very best technology for continuous fluid assessment in the operating room or a critical care setting,” said Chris Hutchison, President and CEO of Cheetah Medical.

The CHEETAH NICOM™ (NonInvasive Cardiac Output Monitoring) system is the only completely noninvasive product designed to provide real-time, continuous, and dynamic monitoring of IV fluids that has been validated against the previous ‘gold standards’ of PAC (Pulmonary Artery Catheter), EDM (Esophageal Doppler Monitoring), and thermo dilution catheter.

Studies* have demonstrated that about half of critically ill patients are not fluid-responsive and cannot increase circulating volume when given additional fluids. Failure to respond to fluids is either because the heart isn’t strong enough to stretch and accommodate the fluid in order to translate the flow, or the vasculature is incapable of doing so. In these cases, excess fluid may result in heart failure, or it may pool in the lungs, with a number of adverse and costly outcomes. On the other hand, insufficient perfusion won’t get enough oxygen to vital organs.

About Cheetah Medical
Headquartered in Newton, Mass., and approved in 60 countries including the U.S., Cheetah Medical is a rapidly growing medical device company with a breakthrough technology, CHEETAH NICOM™, designed to set a new standard of care for noninvasive, beat-to-beat, user- and patient-friendly cardiac output monitoring. CHEETAH NICOM has met with success in patients undergoing Guided Fluid Therapy during surgery, in critical care patients who are being fluid resuscitated to manage sepsis, and in trauma patients who have experienced high fluid loss. To learn more, please visit

* Marik PE, Monnet X, and Teboul JL. Hemodynamic parameters to guide fluid therapy. Annals of Intensive Care 2011;1:1